Opendata, web and dolomites

ECMO-BIOMARKER SIGNED

Delivering ECMO-BIOMARKER – a ground-breaking ICT-enabled ECMO Biomarker system providing clinicians with bedside decision support for better care and reduced costs of severe ICU patients

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ECMO-BIOMARKER project word cloud

Explore the words cloud of the ECMO-BIOMARKER project. It provides you a very rough idea of what is the project "ECMO-BIOMARKER" about.

imperial    severe    ventilation    20    patients    dk    site    160m    clermont    ferrand    brompton    hospitals    26bn    patents    aalborg    acute    medical    empowers    predictive    sales    skilled    accurate    23    quality    conventional    london    physiological    launched    membrane    diagnose    clinically    external    university    instead    lung    48m    ict    minutes    diagnosis    model    tool    royal    respiratory    college    reduce    icu    cut    action    intensive    biomarker    characterised    algorithms    centre    bedside    patient    proposition    hire    uses    perform    diagnostic    rudimentary    hospitalier    universitaire    16    annually    slashing    workflow    centres    blood    function    2025    world    group    corporal    mermaid    machine    referrals    documented    doctors    injury    oxygenation    costing    fr    companion    care    industry    healthcare    market    oxygenized    one    innovation    recommendations    vienna    uk    hospital    ten    employees    first    ecmo    de    tools    extra    potentially    clinical    treatment   

Project "ECMO-BIOMARKER" data sheet

The following table provides information about the project.

Coordinator
MERMAID CARE AS 

Organization address
address: HEDELUND 1
city: NORRESUNDBY
postcode: 9400
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Total cost 3˙558˙966 €
 EC max contribution 2˙851˙191 € (80%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-EIC-FTI-2018-2020
 Funding Scheme IA
 Starting year 2019
 Duration (year-month-day) from 2019-04-01   to  2021-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MERMAID CARE AS DK (NORRESUNDBY) coordinator 1˙651˙475.00
2    IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE UK (LONDON) participant 625˙312.00
3    CENTRE HOSPITALIER UNIVERSITAIRE DE CLERMONT-FERRAND FR (CLERMONT FERRAND) participant 215˙155.00
4    AALBORG UNIVERSITET DK (AALBORG) participant 195˙000.00
5    MEDIZINISCHE UNIVERSITAET WIEN AT (WIEN) participant 164˙248.00

Map

 Project objective

One out of ten ICU respiratory patients are characterised as being “severe”, with a lung function of less than 20% due to acute respiratory failure. This group are often referred to ECMO (Extra Corporal Membrane Oxygenation) treatment, in which the patient’s blood is oxygenized by an external machine, costing European healthcare centres €26Bn annually. The problem is, due to the rudimentary tools that ICU doctors use to diagnose these patients, 20% of all ECMO patients should not have been treated with ECMO and instead could have stayed in conventional intensive ventilation care. Industry partner Mermaid Care aims to solve this problem with ECMO-BIOMARKER – the world’s first biomarker-based companion diagnostic tool for severe lung injury patients. ECMO-BIOMARKER will potentially reduce ECMO referrals by 10-20%, slashing costs for the average European ECMO centre by an estimated €23-48M annually. Based on clinically predictive biomarker measurements, ECMO-BIOMARKER uses novel algorithms and physiological model to deliver accurate diagnosis recommendations for each patient, bedside and in less than 2 minutes. This ICT-approach changes workflow and empowers low-skilled ICU doctors to perform ECMO diagnosis. In the proposed action, ECMO-BIOMARKER value proposition (reduction in ECMO patients) will be clinically documented together with 4 world-leading partners in the field of ICU management and ECMO treatment: 3 clinical research partners – Imperial College London with the clinical site Royal Brompton Hospital (UK), Medical University of Vienna (AT) and Centre Hospitalier Universitaire de Clermont-Ferrand (FR) – and research partner Aalborg University (DK). After the project, ECMO-BIOMARKER is launched on the EU market, allowing European hospitals to cut ICU costs and improve patient quality of care. This project will allow Mermaid Care to reach sales of €160M in 2025 and hire 30 new employees. The innovation is based on 16 years of research and 10 patents.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ECMO-BIOMARKER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ECMO-BIOMARKER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.1.)

PATH-TOX (2018)

Artificial Intelligence to transform Drug and Chemical safety testing

Read More  

GoSafe (2019)

Restoring complete sensory ability for natural walking of amputees

Read More  

GIoT (2019)

Nano-satellites based Global Infrastructure to Enable IoT/M2M Networks - GIoT (Global IoT)

Read More